---
title: "ChemPartner released its half-year performance, turning a profit of 25.3821 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255057030.md"
description: "According to the Zhitong Finance APP, ChemPartner released its semi-annual report for 2025, showing an operating income of 534 million yuan, a year-on-year increase of 14.75%. The net profit attributable to shareholders of the listed company was 25.3821 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6.7923 million yuan. The basic earnings per share were 0.051 yuan"
datetime: "2025-08-28T16:16:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255057030.md)
  - [en](https://longbridge.com/en/news/255057030.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255057030.md)
---

# ChemPartner released its half-year performance, turning a profit of 25.3821 million yuan

According to the Zhitong Finance APP, ChemPartner (300149.SZ) released its semi-annual report for 2025, with operating revenue of 534 million yuan, a year-on-year increase of 14.75%. The net profit attributable to shareholders of the listed company was 25.3821 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6.7923 million yuan. The basic earnings per share were 0.051 yuan

### Related Stocks

- [300149.CN](https://longbridge.com/en/quote/300149.CN.md)

## Related News & Research

- [Key facts: Li Auto L9 uses FlexNoC/Magillem for 2,560 TOPS; shares fall](https://longbridge.com/en/news/286979573.md)
- [LATVIA DEFENCE FORCES: WE CONFIRM THAT THERE IS AT LEAST ONE UNMANNED AERIAL VEHICLE IN LATVIAN AIRSPACE](https://longbridge.com/en/news/287189602.md)
- [Pure Tungsten Completes Merger with GB Innovation Co., Ltd., Advancing Toward Near-Term Production and Planned Public Listing](https://longbridge.com/en/news/286944364.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)